Pliant Therapeutics Inc PLRX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.81 down $0.01, 0.75% at close Nov 6
Last close · Previous close $0.82
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.49Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.81down $0.22, 21.39%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.82Nov 5
- Volume151.61KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume331.34KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.80 to $1.82; now $0.81
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PLRX trailed the S&P 500 in all 6 periods.
| Period | PLRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PLRX: down 21.4% S&P 500: down 5.6% | PLRX trailed the S&P 500 by 15.8 percentage points Trailed |
| 3M | PLRX: down 22.9% S&P 500: down 4.1% | PLRX trailed the S&P 500 by 18.8 percentage points Trailed |
| YTD | PLRX: down 33.6% S&P 500: up 8.7% | PLRX trailed the S&P 500 by 42.3 percentage points Trailed |
| 1Y | PLRX: down 47.1% S&P 500: up 10.9% | PLRX trailed the S&P 500 by 58.0 percentage points Trailed |
| Long term | ||
| 3Y | PLRX: down 94.8% S&P 500: up 75.0% −62.6% vs +20.5% a year | PLRX trailed the S&P 500 by 169.8 percentage points Trailed |
| 5Y | PLRX: down 95.4% S&P 500: up 67.8% −46.0% vs +10.9% a year | PLRX trailed the S&P 500 by 163.2 percentage points Trailed |
$10,000 invested in PLRX 5 years ago (Nov 5, 2021) would be worth about $459 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
PLRX trailed the S&P 500 in all 6 periods.
| Period | PLRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PLRX: down 21.4% S&P 500: down 5.6% | PLRX trailed the S&P 500 by 15.8 percentage points Trailed |
| 3M | PLRX: down 22.9% S&P 500: down 4.3% | PLRX trailed the S&P 500 by 18.6 percentage points Trailed |
| YTD | PLRX: down 33.6% S&P 500: up 7.8% | PLRX trailed the S&P 500 by 41.4 percentage points Trailed |
| 1Y | PLRX: down 47.1% S&P 500: up 9.7% | PLRX trailed the S&P 500 by 56.8 percentage points Trailed |
| Long term | ||
| 3Y | PLRX: down 94.8% S&P 500: up 68.8% −62.6% vs +19.1% a year | PLRX trailed the S&P 500 by 163.6 percentage points Trailed |
| 5Y | PLRX: down 95.4% S&P 500: up 56.9% −46.0% vs +9.4% a year | PLRX trailed the S&P 500 by 152.3 percentage points Trailed |
$10,000 invested in PLRX 5 years ago (Nov 5, 2021) would be worth about $459 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$40.23
Closing high on . Now 98.0% below that record.
Split-adjusted daily closes since Jun 3, 2020.
Stock splits
PLRX hasn’t split since its price history begins in 2020.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$92.29M
- Diluted EPS
- −$1.49
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$57.76M | −$0.95 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$49.73M | −$0.81 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$56.17M | −$0.92 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$43.30M | −$0.71 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$26.30M | −$0.43 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$23.58M | −$0.38 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$20.04M | −$0.32 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$22.37M | −$0.36 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $7.57M | −$97.26M | −$2.71 |
| FY22 (Dec 31, 2022) | $9.69M | −$123.32M | −$2.94 |
| FY23 (Dec 31, 2023) | $1.58M | −$161.34M | −$2.75 |
| FY24 (Dec 31, 2024) | $0.00 | −$210.30M | −$3.47 |
| FY25 (Dec 31, 2025) | $0.00 | −$149.34M | −$2.43 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$70.62MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$70.90MLast 12 months
- Capital spending$274.00KLast 12 months
Shareholder returns
- $146.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $159.58MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$28.74MAs of Jun 30, 2026
- Net cash$130.84MAs of Jun 30, 2026
- 9.90As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.20As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −53.2%Last 12 months
Over the last 12 months, Pliant Therapeutics lost money: its net loss was 53.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −41.3%Last 12 months
Over the last 12 months, Pliant Therapeutics’s net loss was 41.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Pliant Therapeutics Inc
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PLRX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PLRX stock FAQ
What is PLRX stock’s price today?
Pliant Therapeutics (PLRX) traded at $0.81 at the close on , down $0.01 (0.75%) from the previous close of $0.82. Over the past 52 weeks it has traded between $0.80 and $1.82.
If you invested $1,000 in PLRX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PLRX on would be worth about $46 at the close on , a total return of −95.4%. The same $1,000 would be worth $529 if invested one year ago. Past performance doesn’t predict future returns.
What is PLRX’s P/E ratio?
PLRX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.49).
What are PLRX’s earnings per share?
PLRX’s diluted earnings per share were −$1.49 over the four quarters to , compared with −$3.39 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.36 per share, against −$0.71 a year earlier (how EPS works).
Does PLRX pay a dividend?
Pliant Therapeutics hasn’t paid a dividend in the last twelve months.
What is PLRX’s 52-week high and low?
Over the past 52 weeks PLRX has traded as low as $0.80 and as high as $1.82. At $0.81 at the close on , it is 55.4% below that high and 1.8% above the low.
What is PLRX’s all-time high?
PLRX’s highest closing price was $40.23 on , adjusted for stock splits. At $0.81 at the close on , it is 98.0% below that record.
Has PLRX stock ever split?
No. PLRX hasn’t split since its price history begins in 2020.
How has PLRX stock performed?
Including dividends and measured to the close on , PLRX has returned −33.6% so far this year and −47.1% over the past year, and −95.4% over five years (−46.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Pliant Therapeutics in?
Pliant Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does PLRX trade on?
Pliant Therapeutics trades on the Nasdaq under the ticker symbol PLRX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.